Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2021, with a specific reporting date of June 11, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Instrument | Transaction Type | Transaction Date | Price per Share | Total Volume |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition under Share Reward Plan | June 9, 2021 | £13.6195 | 180 shares (aggregate) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share acquisitions by eleven executives and one associated person. All transactions were executed on the London Stock Exchange (XLON) on June 9, 2021, at a uniform price of £13.6195.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The content is strictly limited to regulatory disclosure of share ownership changes.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs (180 shares total across 11 individuals).
- Confirm the transaction price of £13.6195 aligns with the market price on June 9, 2021.
- Note that all transactions were "Acquisitions" under the Share Reward Plan, consisting of partnership and matching shares.
- Identify the specific executives involved, including CEO Emma Walmsley and President of Global Vaccines Richard Connor.